Last reviewed · How we verify
NCT04371003: PROWENI
Prospective Investigation of Oxidative Stress in West Nile Virus Infection
trial in West Nile Virus. Withdrawn.
1 October 2023
Quick facts
| Lead sponsor | Institute of Tropical Medicine, Belgium |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 1 September 2020 |
| Primary completion | 1 October 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across Romania |
Conditions studied
- West Nile Virus — all drugs for West Nile Virus →
- West Nile Fever — all drugs for West Nile Fever →
- West Nile Fever Encephalitis — all drugs for West Nile Fever Encephalitis →
- West Nile Fever Meningitis — all drugs for West Nile Fever Meningitis →
Sponsor
Institute of Tropical Medicine, Belgium
Who can join
18 and older, any sex, with West Nile Virus or West Nile Fever. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigator hypothesizes that oxidative stress responses to West Nile virus infection in the central nervous system determine the severity of infection and the long-term neurological, neuropsychological and functional sequelae of West Nile Neuroinvasive Disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04371003
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for West Nile Virus
Currently open trials in the same condition.
- NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
- NCT06510426 — Early Interferon-beta Treatment for West-Nile Virus Infection · Phase 2 · recruiting
- NCT06640660 — Investigating Visuo-spatial Abilities and Psychological Effects in West Nile and Multiple Sclerosis Patients with a Focu · NA · recruiting
Other Institute of Tropical Medicine, Belgium trials
Trials by the same sponsor.
- NCT07463040 — Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL) · Phase 3 · not yet recruiting
- NCT07174648 — Testing of a New Rapid Antigen Test for Plague in Ituri, Democratic Republic of the Congo. · not yet recruiting
- NCT07499739 — Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination (MBOTE-TRAXX) · Phase 4 · not yet recruiting
- NCT07342829 — Prospective Follow-up After MVA-BN Booster Vaccination · not yet recruiting
- NCT06839989 — An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04371003 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Tropical Medicine, Belgium
- Last refreshed: 10 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04371003.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing